Is Insulet Stock Underperforming the Nasdaq?

Company Overview - Insulet Corporation (PODD) is a medical technology company based in Acton, Massachusetts, specializing in innovative insulin delivery solutions for diabetes management [1] - The company has a market capitalization of $20.5 billion and is recognized for its Omnipod® Insulin Management System, a tubeless, wearable insulin pump [1][2] Market Position - PODD is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical devices industry [2] - The company primarily targets individuals with Type 1 diabetes and insulin-dependent Type 2 diabetes, positioning itself as a significant player in the global diabetes care market [2] Stock Performance - Shares of PODD have decreased by 17% from its 52-week high of $354.88, reached on November 20, and have declined 11.2% over the past three months, underperforming the Nasdaq Composite's 2.9% increase during the same period [3] - Over the past 52 weeks, PODD's stock has gained 11.1%, which is lower than the Nasdaq's 14% increase, and on a year-to-date basis, shares are up 12.9% compared to the Nasdaq's 19.1% return [4] Recent Financial Performance - PODD reported better-than-expected Q3 earnings on November 6, with total revenue increasing by 29.9% year-over-year to $706.3 million, surpassing consensus estimates by 4.4% [5] - The adjusted EPS rose by 37.8% from the previous year to $1.24, exceeding analyst expectations of $1.13, leading the company to raise its fiscal 2025 revenue growth guidance to a range of 28% to 29% [5] Competitive Landscape - PODD has underperformed compared to its rival, Medtronic plc (MDT), which has seen a stock increase of 20% over the past 52 weeks and 22.2% on a year-to-date basis [6]